糖蛋白
免疫系统
抗体
艾滋病疫苗
人类免疫缺陷病毒(HIV)
大流行
病毒包膜
艾滋病疫苗
中和抗体
2019年冠状病毒病(COVID-19)
免疫学
病毒
计算生物学
医学
病毒学
生物
疫苗试验
遗传学
疾病
病理
传染病(医学专业)
作者
Xiaoqian Xin,Yifeng Liu,Lei Guo,Hui Wang,Daiqiang Lu,Yaotian Chang,Mingming Wan,Yong Zhang,Yaming Shan,Qiao Zhang,Xiaowen Liu,Feng Gao
出处
期刊:Nano Letters
[American Chemical Society]
日期:2023-04-30
卷期号:23 (9): 4090-4094
被引量:6
标识
DOI:10.1021/acs.nanolett.3c01241
摘要
The human immunodeficiency virus (HIV) has infected over 84 million people since its discovery and is a huge threat to human health. While an HIV vaccine is urgently needed to curb this devastating pandemic, it has been notoriously difficult to develop, partly due to the extraordinary high level of genetic variation of HIV. We designed a new HIV-1 envelope glycoprotein nanoparticle (Env/NP) vaccine using amphiphilic polymers. The Env/NP vaccine induced more potent and broader neutralizing activities against multiple HIV-1 subtypes. Moreover, it elicits similar neutralizing antibody responses after the storage at −80 °C, 4 °C or room temperature post lyophilization. These results demonstrate that the new Env/NP vaccine not only improves the HIV vaccine immune responses but also is stable under different storage conditions. This new nanovaccine approach can readily apply to other protein-based vaccines.
科研通智能强力驱动
Strongly Powered by AbleSci AI